

List of Publications by Year in  
Descending Order

**Source:** <https://exaly.com/author-pdf/9377385/lucie-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119 papers	6,154 citations	36 h-index	77 g-index
125 ext. papers	7,785 ext. citations	4.9 avg, IF	5.45 L-index

#	Paper	IF	Citations
119	Explainable artificial intelligence in skin cancer recognition: A systematic review.. <i>European Journal of Cancer</i> , <b>2022</b> , 167, 54-69	7.5	6
118	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 765608	5.3	1
117	Clinical determinants of long-term survival in metastatic uveal melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	0
116	Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy. <i>Journal of Immunotherapy</i> , <b>2021</b> , 44, 114-117	5	1
115	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1503-1516	15.1	28
114	Upregulation of CCR4 in activated CD8 T cells indicates enhanced lung homing in patients with severe acute SARS-CoV-2 infection. <i>European Journal of Immunology</i> , <b>2021</b> , 51, 1436-1448	6.1	12
113	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 170-181	7.5	11
112	Inflammatory markers in autoimmunity induced by checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 1623-1630	4.9	9
111	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 37-48	7.5	3
110	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 1-10	7.5	4
109	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 672172	5.3	1
108	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 61-75	7.5	5
107	Response to letter entitled: Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 272-273	7.5	1
106	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. <i>European Journal of Cancer</i> , <b>2021</b> , 152, 139-154	7.5	4
105	A benchmark for neural network robustness in skin cancer classification. <i>European Journal of Cancer</i> , <b>2021</b> , 155, 191-199	7.5	6
104	Checkpoint-Inhibition bei Tumorerkrankungen. <i>Onkologe</i> , <b>2021</b> , 27, 1075	0.1	
103	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. <i>European Journal of Cancer</i> , <b>2021</b> , 156, 202-216	7.5	16

102	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. <i>OncImmunology</i> , <b>2020</b> , 9, 1774298	7.2	13
101	The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
100	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 582-609	16.2	11
99	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , <b>2020</b> , 141, 2031-2034	16.7	60
98	Merkel Cell Carcinoma of the Head and Neck Compared to Other Anatomical Sites in a Real-World Setting: Importance of Surgical Therapy for Facial Tumors. <i>Facial Plastic Surgery</i> , <b>2020</b> , 36, 249-254	1.2	2
97	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , <b>2020</b> , 41, 1733-1743	9.5	114
96	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 467-478	15.1	87
95	The Role of Immune Checkpoint Blockade in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	23
94	Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease. <i>Cancer Medicine</i> , <b>2020</b> , 9, 6132-6140	4.8	3
93	ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. <i>Anticancer Research</i> , <b>2020</b> , 40, 4937-4946	2.3	4
92	Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
91	C-reactive protein as an early marker of immune-related adverse events. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 2625-2631	4.9	24
90	Checkpoint Inhibitors. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2019</b> , 116, 119-126	2.5	42
89	Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma. <i>BMC Cancer</i> , <b>2019</b> , 19, 207	4.8	10
88	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. <i>European Journal of Cancer</i> , <b>2019</b> , 111, 148-154	7.5	115
87	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1299-1307.e7	4.5	4
86	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. <i>European Journal of Cancer</i> , <b>2019</b> , 112, 29-31	7.5	12
85	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors <b>2019</b> , 7, 53		42

84	Non-professional phagocytosis: a general feature of normal tissue cells. <i>Scientific Reports</i> , <b>2019</b> , 9, 118754.9	28
83	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study <b>2019</b> , 7, 299	52
82	Melanom <b>2019</b> , 45-134	
81	In Reply. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2019</b> , 116, 363-364	2.5
80	Senescence markers: Predictive for response to checkpoint inhibitors. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1147-1150	7.5 19
79	Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity. <i>Nature Microbiology</i> , <b>2019</b> , 4, 164-176	26.6 23
78	c-Rel is a cell cycle modulator in human melanoma cells. <i>Experimental Dermatology</i> , <b>2019</b> , 28, 121-128	4 2
77	Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2019</b> , 106, 12-23	7.5 111
76	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 825-834	7.4 63
75	A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2018</b> , 1864, 2315-2328	6.9 12
74	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 785-792	8.7 25
73	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1755-1764	15.1 572
72	Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. <i>Journal of Immunotherapy</i> , <b>2018</b> , 41, 35-38	5 42
71	BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3 11
70	Willingness to pay for a cure of low-risk melanoma patients in Germany. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197780	3.7 6
69	Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports <b>2018</b> , 6, 2	8
68	Fear of cancer progression in patients with stage IA malignant melanoma. <i>European Journal of Cancer Care</i> , <b>2018</b> , 27, e12901	2.4 9
67	Immune-Related Adverse Toxicities and Clinical Management <b>2018</b> , 577-589	

66	The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. <i>Oncotarget</i> , <b>2018</b> , 9, 26217-26225	3.3	3
65	Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. <i>Oncotarget</i> , <b>2018</b> , 9, 28903-28909	3.3	28
64	BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. <i>Anticancer Research</i> , <b>2018</b> , 38, 1335-1341	2.3	8
63	Can checkpoint inhibitor therapy improve response to chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 183-185	4.9	0
62	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. <i>European Journal of Cancer</i> , <b>2018</b> , 98, 10-16	7.5	34
61	Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. <i>Immunotherapy</i> , <b>2017</b> , 9, 115-121	3.8	62
60	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. <i>European Journal of Cancer</i> , <b>2017</b> , 75, 24-32	7.5	118
59	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , <b>2017</b> , 75, 47-55	7.5	99
58	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 1977-1984	4.9	11
57	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 57, 36-49	14.4	185
56	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 56-65	7.5	109
55	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. <i>European Journal of Cancer</i> , <b>2017</b> , 81, 36-44	7.5	50
54	The tanning habits and interest in sunscreen of Google users: what happened in 12 years?. <i>Photodermatology Photoimmunology and Photomedicine</i> , <b>2017</b> , 33, 68-74	2.4	11
53	Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). <i>Klinische Padiatrie</i> , <b>2017</b> , 229, 322-328	0.9	13
52	Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	56
51	A review of serious adverse effects under treatment with checkpoint inhibitors. <i>Current Opinion in Oncology</i> , <b>2017</b> , 29, 136-144	4.2	45
50	Interest in tanning beds and sunscreen in German-speaking countries. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2017</b> , 15, 1192-1198	1.2	4
49	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy <b>2016</b> , 4, 50		311

48	Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 662-81	1.2	33
47	Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 662-83	1.2	36
46	Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011. <i>BMC Cancer</i> , <b>2016</b> , 16, 936	4.8	19
45	Preferences of German melanoma patients for interferon (IFN) $\alpha$ 2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5375	1.8	8
44	Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. <i>OncImmunology</i> , <b>2016</b> , 5, e1128611	7.2	47
43	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. <i>Oncotarget</i> , <b>2016</b> , 7, 36130-36137	3.3	8
42	Predicting the response to anti-PD1 therapy in metastatic melanoma. <i>Translational Cancer Research</i> , <b>2016</b> , 5, S576-S579	0.3	2
41	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5487-5496	12.9	373
40	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , <b>2016</b> , 60, 210-25	7.5	391
39	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , <b>2016</b> , 60, 190-209	7.5	412
38	Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. <i>European Journal of Cancer</i> , <b>2016</b> , 65, 182-4	7.5	30
37	Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients. <i>Dermatology</i> , <b>2015</b> , 231, 127-33	4.4	9
36	Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab. <i>Journal of Immunotherapy</i> , <b>2015</b> , 38, 212-5	5	42
35	Evaluating HIV Prevention Programs: Herpes Simplex Virus Type 2 Antibodies as Biomarker for Sexual Risk Behavior in Young Adults in Resource-Poor Countries. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128370	3.7	5
34	Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy. <i>Strahlentherapie Und Onkologie</i> , <b>2014</b> , 190, 1169-72	4.3	27
33	Drug-induced dilemma: angiokeratomas and decreased renal function. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 598-600	2.4	4
32	Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. <i>PLoS ONE</i> , <b>2014</b> , 9, e111237	3.7	25
31	Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma. <i>Melanoma Research</i> , <b>2014</b> , 24, 322-31	3.3	2

30	T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 235ra60	17.5	110
29	Melanom <b>2014</b> , 31-97		
28	The skin prick test - European standards. <i>Clinical and Translational Allergy</i> , <b>2013</b> , 3, 3	5.2	366
27	Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. <i>British Journal of Cancer</i> , <b>2013</b> , 108, 2164-71	8.7	77
26	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. <i>PLoS ONE</i> , <b>2013</b> , 8, e53745	3.7	343
25	Is drug allergy less prevalent than previously assumed? A 5-year analysis. <i>British Journal of Dermatology</i> , <b>2012</b> , 166, 107-14	4	26
24	Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e356-7	2.2	34
23	Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. <i>Journal of Immunotherapy</i> , <b>2011</b> , 34, 58-64	5	32
22	Acute generalized exanthematous pustulosis induced by methylphenidate: a new adverse effect. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 872-3		8
21	Sarcoidosis induced by interferon- $\gamma$ in melanoma patients: incidence, clinical manifestations, and management strategies. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 834-9	5	30
20	Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. <i>Dermatology</i> , <b>2007</b> , 215, 325-30	4.4	27
19	Interleukin-2: a potential treatment option for postherpetic neuralgia?. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43, e109-10	11.6	3
18	Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. <i>Vaccine</i> , <b>2006</b> , 24, 1389-94	4.1	15
17	Sublingual immunotherapy. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2006</b> , 4, 428-33; quiz 434-5	1.2	1
16	Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. <i>Journal of Investigative Dermatology</i> , <b>2006</b> , 126, 2525-32	4.3	21
15	Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. <i>Journal of Clinical Immunology</i> , <b>2006</b> , 26, 347-59	5.7	33
14	Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. <i>Human Gene Therapy</i> , <b>2005</b> , 16, 35-48	4.8	119
13	Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. <i>Blood</i> , <b>2005</b> , 106, 2287-94	2.2	134



12	Attitudes of traditional healers towards Western medicine in rural Cameroon. <i>Tropical Doctor</i> , <b>2005</b> , 35, 161-4	0.9	10
11	IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. <i>Experimental Dermatology</i> , <b>2004</b> , 13, 380-90	4	29
10	Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. <i>Experimental Dermatology</i> , <b>2002</b> , 11, 232-40	4	36
9	Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. <i>Cancer Gene Therapy</i> , <b>2002</b> , 9, 289-95	5.4	30
8	Fucosyltransferase VII-deficient mice with defective E-, P-, and L-selectin ligands show impaired CD4+ and CD8+ T cell migration into the skin, but normal extravasation into visceral organs. <i>Journal of Immunology</i> , <b>2002</b> , 168, 2139-46	5.3	69
7	Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient. <i>European Journal of Dermatology</i> , <b>2002</b> , 12, 194-7	0.8	17
6	Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. <i>Journal of Molecular Medicine</i> , <b>2001</b> , 78, 692-702	5.5	65
5	Cutaneous ulceration after injection of polyethylene-glycol-modified interferon alpha associated with visual disturbances in a melanoma patient. <i>Dermatology</i> , <b>2000</b> , 201, 154-7	4.4	13
4	Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. <i>Cancer</i> , <b>2000</b> , 89, 1835-1844	6.4	98
3	Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. <i>Cancer Gene Therapy</i> , <b>2000</b> , 7, 1557-65	5.4	27
2	Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. <i>Archives of Dermatology</i> , <b>2000</b> , 136, 374-8		64
1	Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. <i>Journal of Clinical Virology</i> , <b>1999</b> , 13, 17-27	14.5	30